These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29705789)

  • 41. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdörfer F; de Leve S; Jendrossek V
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
    Cheng X; Zhao G; Zhao Y
    Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment.
    Printz C
    Cancer; 2018 Mar; 124(6):1097-1098. PubMed ID: 29509327
    [No Abstract]   [Full Text] [Related]  

  • 48. The importance for immunoregulation for long-term cancer control.
    Fusi A; Dalgleish A
    Future Oncol; 2017 Aug; 13(18):1619-1632. PubMed ID: 28776411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Wang W; Zou W; Liu JR
    Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
    [No Abstract]   [Full Text] [Related]  

  • 50. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
    Beyar-Katz O; Gill S
    Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
    Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
    Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunotherapy of colorectal cancer: new perspectives after a long path.
    Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
    Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies to relieve immunosuppression in pancreatic cancer.
    Schnurr M; Duewell P; Bauer C; Rothenfusser S; Lauber K; Endres S; Kobold S
    Immunotherapy; 2015; 7(4):363-76. PubMed ID: 25917628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recent progress in therapeutic antibodies for cancer immunotherapy.
    Lee A; Sun S; Sandler A; Hoang T
    Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy for pancreatic cancer: A 2020 update.
    Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
    Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.